Spin-out companies
Companies that have been spun out from Brunel University London, and our academic research, include:
HecoAnalytics
This is an easy-to-use health analytics platform that supports MedTech companies to gain the capability needed to robustly assess and sell their products to a global digital health economy. The HecoAnalytics approach can be used to benefit medical devices and software, including AI, by creating actionable evidence from literature and scenario-based modelling tools.
TestAVec
A scientific leader in genetic toxicology, TestAVec has developed the world's first patented human-stem-cell-based in vitro testing service to reduce the genotoxic risk of gene therapy products. Aiming to identify, reduce and eventually replace the use of animal models that can give biased oncogenic outreads, TestAVec's ambition is to bolster confidence in gene therapy products and their application and to accelerate the time taken for gene therapies to reach the clinic.
Vidiia
Vidiia is a game-changing team of medical, technology and operational experts brought together to pursue a new breed of low-cost disease diagnostics deployable anywhere in the field, by anyone. Their purpose is to accelerate diagnostic development, enabling small-scale, smart, remote disease testing using Vidiia's AI-powered technologies.
Phyona
Pioneering research at Brunel has resulted in the development of extraction and synthesis processes that recover metals from contaminated soil and other substrates, converting them into high-value nanoparticles for use in manufacturing. Phyona valorises a resource that would otherwise be treated as a nuisance.